Correlations between peripheral blood biomarkers and clinical outcomes in advanced non-small cell lung cancer patients who received immunotherapy-based treatments

Shi, Yuequan; Liu, Xiaoyan; Liu, Jia; Zhang, Dongming; Liu, Xiangning; Yue, Yuan; Zhou, Qing; Gao, Xing; Chen, Minjiang; Xu, Yan; Zhao, Jing; Zhong, Wei; Provencio, Mariano; Jassem, Jacek; Williams, Terence M.; Seeber, Andreas; Kocher, Florian; Wang, Mengzhao

doi:10.21037/tlcr-21-710

Cited by 22 publications

(24 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several potential risk factors for the development of irAEs from ICIs have been suggested, including interleukin (IL)-17, eosinophil counts, absolute lymphocyte count, preexisting autoimmune diseases (AIDs), and so on (9)(10)(11)(12)(13)(14). Furthermore, previous studies indicated that preexisting anti-thyroglobulin (ATG) and anti-thyroid peroxidase (ATPO) were more common among patients receiving ICIs who subsequently developed thyroid dysfunction (15,16).…”

Section: Introductionmentioning

confidence: 99%

Safety and efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients with preexisting antinuclear antibodies: a retrospective cohort study

Zhang¹,

Shi²,

Liu³

et al. 2022

Transl Lung Cancer Res

Self Cite

View full text Add to dashboard Cite

Background: Antinuclear antibodies (ANAs) predicting the safety and efficacy of patients with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs) are still a matter of debate considering previous studies showed quite different results based on different ANA cut-off values.Thus, we investigated the associations between different ANA titers and the safety and efficacy of ICIs.Moreover, we also briefly discussed the effects of anti-thyroglobulin (ATG) and anti-thyroid peroxidase (ATPO) on the safety of ICIs.Methods: A total of 159 Chinese patients confirmed to have locally-advanced or metastatic NSCLC given ICIs or chemoimmunotherapy in Peking Union Medical College Hospital from January 2015 to December 2020 were analyzed retrospectively and were followed up until December 2020 or death or loss to followup. Patients' characteristics were retrieved from medical records. ANAs were detected by the indirect immunofluorescence assay, ATG and ATPO by the electrochemiluminescence immunoassay. The severity of immune-related adverse events (irAEs) was graded according to the Common Terminology Criteria for Adverse Events (CTCAE 5.0) and the efficacy was evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Results:The incidence of irAEs, median progression-free survival (mPFS) of the ANA negative and positive groups were 26.0% vs. 31.4% (P=0.457), 17.7 vs. 10 months (P=0.603) for the cut-off value of 1:80; 26.2% vs. 33.9% (P=0.305), 11.9 vs. 10.6 months (P=0.957) for 1:160; and 25.9% vs. 45.8% (P=0.047), and 11.9 vs. 7.7 months (P=0.471) for 1:320, separately. Besides, ANA titer ≥1:320 was associated with irAEs [odds ratio (OR) =4.9, 95% confidence interval (CI): 1.45-16.52, P=0.01] and the incidence of adverse skin reactions differed greatly between the negative and positive groups (9.7% vs. 32%, P=0.003). Moreover, a total of 52 out of 159 patients were tested for ATG and ATPO. 46 patients were negative and 6 were positive, with the incidence of abnormal thyroid function being 4.3% vs. 50% (P=0.005), respectively.Conclusions: Preexisting ANAs may not correlate with the clinical benefit of immunotherapy in patients with NSCLC but may be associated with adverse skin reactions. Besides, ATG or ATPO has the potential to

show abstract

Section: Introductionmentioning

confidence: 99%

Safety and efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients with preexisting antinuclear antibodies: a retrospective cohort study

Zhang¹,

Shi²,

Liu³

et al. 2022

Transl Lung Cancer Res

Self Cite

View full text Add to dashboard Cite

show abstract

“…These 8 studies examined 831 patients with lung cancer who received ICI-based therapy, and all of them examined patients from East Asia (China and Japan). Six studies examined the association of pretreatment PNI with OS and PFS, [ 14 , 15 , 17 , 19 – 21 ] 1 study only examined the relationship of pretreatment PNI with PFS, [ 18 ] and 1 study only examined the relationship of pretreatment PNI with OS. [ 16 ] One publications [ 15 ] contained more precise groupings, so we separated the data from this article and recorded it as “Shi 2021-1” and “Shi 2021-2.” All 8 studies were retrospective and all had NOS scores of 7 or 8, indicating they were “high quality” studies.…”

Section: Resultsmentioning

confidence: 99%

Pretreatment “prognostic nutritional index” as an indicator of outcome in lung cancer patients receiving ICI-based treatment: Systematic review and meta-analysis

et al. 2022

View full text Add to dashboard Cite

Background: The pretreatment prognostic nutritional index (PNI) is an indicator of nutritional and immune status, and has potential use as a predictor of survival in cancer patients. Several retrospective studies have used the PNI to predict the outcome of lung cancer patients receiving different immune checkpoint inhibitors (ICIs), but the results have been inconsistent. The objective of our study is to assess the relationship of pretreatment PNI with survival outcomes in lung cancer patients who received ICIbased treatments by meta-analysis.Methods: We searched the EMBASE, PubMed, Cochrane Library, American Society of Clinical Oncology, and European Society of Medical Oncology databases to identify studies that reported overall survival (OS) or progression-free survival (PFS) in eligible patients. Eight studies were eligible based on predefined inclusion and exclusion criteria. Data and pooled indicators were extracted from these studies. Meta-analysis was used to analyze hazard ratios (HRs) and 95% confidence intervals (CIs) for OS and/or PFS and the prognostic value of pretreatment PNI. We completed the registration of the research protocol (Registration number: INPLASY202240087,

show abstract

“…In addition, the local infiltration of CD8 + T lymphocytes in the skin and hair follicles was also related to immunotherapy-related psoriasis, such as dermatitis [38] and alopecia [39]. Wang et al also found that pretreatment absolute lymphocyte count was related to an increased risk of irAEs [40]. However, there is still no report on the relationship between lymphocyte taxonomic count and irAEs.…”

Section: Discussionmentioning

confidence: 99%

Establishment and validation of nomogram for predicting immuno checkpoint inhibitor related pneumonia

Wang

et al. 2022

BMC Pulm Med

View full text Add to dashboard Cite

Objective Cancer is one of the main causes of death worldwide. Although immunotherapy brings hope for cancer treatment, it is also accompanied by immune checkpoint inhibitor-related adverse events (irAEs). Immune checkpoint inhibitor pneumonia (CIP) is a potentially fatal adverse event, but there is still a lack of effective markers and prediction models to identify patients at increased risk of CIP. Methods A total of 369 cancer patients treated between 2017 and 2022 with immune checkpoint inhibitors at Shengjing Hospital of China Medical University and Liaoning People's Hospital were recruited for this study. Independent variables were selected by differences and binary logistic regression analysis, and a risk assessment nomogram was constructed for CIP risk. The accuracy and discriminative abilities of the nomogram were evaluated by calibration plots, receiver operating characteristic curves (ROCs) and decision curve analyses (DCAs). Results Binary logistic regression analysis showed that smoking history, acute phase proteins [interleukin (IL-6) and C-reactive protein (CRP)], CD8 + T lymphocyte count and serum alveolar protein [surface protein-A (SP-A) and Krebs Von den Lungen-6 (KL-6)] were significantly associated with CIP risk. A nomogram consisting of these variables was established and validated by different analyses. Conclusions We developed an effective risk nomogram for CIP prediction in immune-checkpoint inhibitor administrated cancer patients, which will further assist early detection of immunotherapy-related adverse events.

show abstract

Correlations between peripheral blood biomarkers and clinical outcomes in advanced non-small cell lung cancer patients who received immunotherapy-based treatments

Cited by 22 publications

References 50 publications

Safety and efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients with preexisting antinuclear antibodies: a retrospective cohort study

Safety and efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients with preexisting antinuclear antibodies: a retrospective cohort study

Pretreatment “prognostic nutritional index” as an indicator of outcome in lung cancer patients receiving ICI-based treatment: Systematic review and meta-analysis

Establishment and validation of nomogram for predicting immuno checkpoint inhibitor related pneumonia

Contact Info

Product

Resources

About